Solasia Pharma K.K. Share Price Börse Stuttgart

Equities

9SO

JP3436500007

Pharmaceuticals

Market Closed - Börse Stuttgart 11:45:15 31/05/2024 am IST 5-day change 1st Jan Change
0.151 EUR -0.66% Intraday chart for Solasia Pharma K.K. -3.82% -44.89%

Financials

Sales 2024 * 1.66B 10.53M 9.71M 879M Sales 2025 * 1.72B 10.91M 10.06M 910M Capitalization 5.41B 34.35M 31.67M 2.87B
Net income 2024 * -538M -3.42M -3.15M -285M Net income 2025 * -926M -5.88M -5.43M -491M EV / Sales 2024 * 3.17 x
Net cash position 2024 * 161M 1.02M 943K 85.36M Net Debt 2025 * 627M 3.98M 3.67M 332M EV / Sales 2025 * 3.51 x
P/E ratio 2024 *
-9.05 x
P/E ratio 2025 *
-6.19 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.69%
More Fundamentals * Assessed data
Dynamic Chart
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 CI
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study MT
More news
1 week-3.82%
1 month+2.03%
3 months-30.09%
6 months-37.60%
Current year-44.89%
More quotes
1 week
0.15
Extreme 0.151
0.16
1 month
0.14
Extreme 0.136
0.16
3 years
0.14
Extreme 0.136
1.20
5 years
0.14
Extreme 0.136
1.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/07/01
Founder - 01/06/01
Director of Finance/CFO 56 01/14/01
Members of the board TitleAgeSince
Director/Board Member 69 01/14/01
Chief Executive Officer 63 01/07/01
Director of Finance/CFO 56 01/14/01
More insiders
Date Price Change
31/24/31 0.151 -0.66%
30/24/30 0.152 -2.56%
29/24/29 0.156 -3.70%
28/24/28 0.162 -.--%
27/24/27 0.162 +3.18%

Delayed Quote Börse Stuttgart, May 31, 2024 at 11:45 am IST

More quotes
Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
28 JPY
Average target price
100 JPY
Spread / Average Target
+257.14%
Consensus